Autolus Therapeutics plc
Research Autolus Therapeutics plc (AUTL) on Bullrun: market cap USD 463.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAUTL
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 463.12M
- Financial periodQ2 2026
- RevenueUSD 45.69M
- Net income-USD 39.11M
- Free cash flow-USD 25.98M
- Gross margin55.2%
Valuation Snapshot
latest market cap is USD 463.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 75.39M | -USD 287.53M | -USD 302.61M | -27.8% | -1.08 | USD 104.13M | USD 71.39M | USD 178.13M |
| FY2024 | USD 10.12M | -USD 220.66M | -USD 228.35M | -12.5% | -0.86 | USD 227.38M | USD 52.63M | USD 427.33M |
| FY2023 | USD 1.70M | -USD 208.38M | -USD 156.57M | 100.0% | -1.2 | USD 239.57M | USD 52.97M | USD 111.47M |
| FY2022 | USD 6.19M | -USD 148.84M | -USD 123.15M | n/a | -1.57 | USD 382.44M | USD 24.26M | USD 298.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 463.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 529.63M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 625.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.12B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 328.81M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 471.81M | n/a | n/a | n/a |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Autolus Therapeutics plc's market cap?
Autolus Therapeutics plc's market capitalization is USD 463.12M.
What does Autolus Therapeutics plc do?
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.